Loading
Life sciences · Journal article
Diagnostic and Interventional Radiology · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
PURPOSE: Hemoptysis is a life-threatening complication in patients with lung malignancy. Although arterial embolization provides reliable immediate hemostasis, recurrence rates in the oncologic setting substantially exceed those observed in benign disease. Whether routine baseline clinical and tumor characteristics can identify patients at higher risk of post-embolization rebleeding remains unclear. METHODS: We conducted a 5-year single-center retrospective cohort study of 126 consecutive patients with histologically confirmed lung cancer treated with arterial embolization for hemoptysis (January 2021-December 2025). The hemoptysis-free interval was estimated using the Kaplan-Meier method and compared across subgroups using the log-rank test. Associations between prespecified covariates and recurrence were assessed using multivariable Cox proportional hazards regression. Embolic materials included metallic microcoils, polyvinyl alcohol particles (300-700 μm), gelatin sponge, and combinations thereof. Five covariates were examined: tumor diameter, cancer stage, histological subtype, age, and sex. RESULTS: = 0.761). The events-per-variable ratio was approximately 6.4. Major complications occurred in 2.4% of patients (3/126), with no clinically adjudicated procedure-related mortality or permanent neurological sequelae. CONCLUSION: In this exploratory single-center cohort, arterial embolization achieved high technical success with an acceptable short-term safety profile. The evaluated baseline clinical and tumor characteristics were not statistically associated with hemoptysis recurrence; however, the limited event count and absence of key angiographic and oncologic treatment variables preclude definitive conclusions regarding their predictive value. CLINICAL SIGNIFICANCE: Standard tumor burden descriptors alone appeared insufficient for post-embolization recurrence risk stratification in this exploratory cohort. Future models should prioritize angiographic vascular anatomy, collateral supply, prior thoracic radiotherapy, and concurrent systemic anticancer therapy.